Education
About Us
Working with TipRanks
Follow Us
Vor Biopharma, Inc. (VOR)
:VOR
VOR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.63 - $65.80
Previous CloseN/A
Volume424.02K
Average Volume (3M)361.50K
Market Cap
$244.13M
Enterprise Value-$38.26K
Total Cash (Recent Filing)$200.56M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta4.23
Next Earnings
Mar 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding6,841,134
10 Day Avg. Volume594,850
30 Day Avg. Volume361,500
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)0.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.76
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue-0.01
Enterprise Value/Gross Profit0.02
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$57.50Price Target Upside70.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
LeadershipRecent executive-level additions, particularly the hiring of a Chief Development Officer with a successful track record, have bolstered confidence in the leadership team's ability to execute a strategy for long-term value creation.
Product ProspectsTelitacicept has achieved multiple regulatory approvals and treated over 70,000 patients, suggesting potential for success in larger global markets.
Strategic AgreementsVor announced an exclusive license agreement with RemeGen Co., Ltd to develop and commercialize telitacicept in ex-Greater China geographies.
Bears Say
Competitive LandscapeThe competitive landscape is becoming increasingly dense with other molecules, which may challenge telitacicept's market position.
Financial PerformanceVor Bio reported a net loss of $12.56 per share for 2Q25, compared to the consensus estimated net loss of $2.92 per share.
Vor Biopharma News
VOR FAQ
What was Vor Biopharma, Inc.’s price range in the past 12 months?
Vor Biopharma, Inc. lowest stock price was $2.63 and its highest was $65.80 in the past 12 months.
What is Vor Biopharma, Inc.’s market cap?
Vor Biopharma, Inc.’s market cap is $244.13M.
When is Vor Biopharma, Inc.’s upcoming earnings report date?
Vor Biopharma, Inc.’s upcoming earnings report date is Mar 19, 2026 which is in 161 days.
How were Vor Biopharma, Inc.’s earnings last quarter?
Vor Biopharma, Inc. released its earnings results on Aug 07, 2025. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.438 by $0.178.
Is Vor Biopharma, Inc. overvalued?
According to Wall Street analysts Vor Biopharma, Inc.’s price is currently Undervalued.
Does Vor Biopharma, Inc. pay dividends?
Vor Biopharma, Inc. does not currently pay dividends.
What is Vor Biopharma, Inc.’s EPS estimate?
Vor Biopharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vor Biopharma, Inc. have?
Vor Biopharma, Inc. has 6,841,134 shares outstanding.
What happened to Vor Biopharma, Inc.’s price movement after its last earnings report?
Vor Biopharma, Inc. reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.438. Following the earnings report the stock price went down -0.957%.
Which hedge fund is a major shareholder of Vor Biopharma, Inc.?
Currently, no hedge funds are holding shares in VOR
Vor Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$57.50 (70.12% Upside)
$57.50 (70.12% Upside)
Blogger Sentiment
Neutral
VOR Sentiment 50%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $13.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
144.89%
12-Months-Change
Fundamentals
Return on Equity
-125.43%
Trailing 12-Months
Asset Growth
45.05%
Trailing 12-Months
Company Description
Vor Biopharma, Inc.
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
VOR Stock 12 Month Forecast
Average Price Target
$57.50
▲(70.12% Upside)
Technical Analysis
Zentalis Pharmaceuticals
―
Pliant Therapeutics
―
C4 Therapeutics
―
Aziyo Biologics
―
Senti Biosciences
―
Ownership Overview
Currently, No data available
---